+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibiotics Market by Class, Drug Origin, Spectrum of Activity, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4744610
  • Report
  • Region: Global
  • 282 pages
  • Allied Analytics LLP
1 of 4
Antibiotics Market Overview:

The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.

Antibiotic is an antimicrobial substance, which are used in the treatment and prevention of bacterial infections, as well as used rarely to combat protozoan infections. Antibiotics are the medicines that either discontinue bacteria from growing or destroy bacteria straight referred as bacteriostatic and bactericidal antibiotics respectively. Easy accessibility of antibiotics at drug stores and in hospitals with prescription or without prescription fuels their consumption across the world. Moreover, increases antibiotics demand during transplants, dialysis, suppressed immune system, joint replacement, and others boosts the market growth.

Surge in demand for antibiotics, owing to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases are the key factors that boost the growth of the global antibiotics market. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials to determine safety & efficacy of the antibiotics drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for regulatory approval are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer lucrative opportunities for the market players.

The global antibiotics market is segmented based on class, drug origin, spectrum of activity, route of administration, and region. On the basis of class, the market is classified as beta lactam & beta lactamase inhibitors, macrolides, quinolones, and others. The beta lactam & beta lactamase inhibitors segment is further segmented into penicillin, cephalosporin, monobactam, and carbapenem. Depending on drug origin, the antibiotics market is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. Based on route of administration, it is segregated into oral, intravenous, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Antibiotics Market:

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

Antibiotics Key Market Segments:

By Class

Beta Lactam & Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Carbapenem
Monobactam
Quinolones
Macrolides
Others

By Drug Origin

Natural
Semisynthetic
Synthetic

By Spectrum of Activity

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Route of Administration

Oral
Intravenous
Others

By Region

North America
U.S.
Canada
Mexico

Europe
Germany
France
Spain
Italy
UK
Rest of Europe

Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific

LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

The other players in the value chain include (profiles not included in the report):

Aurobindo Pharma
Bayer HealthCare
Eli Lilly
Lupin Pharmaceuticals
Sun Pharmaceutical
Shionogi
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3.1. Top winning strategies
3.4. Market share analysis, 2017
3.5. Porters five forces analysis
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increased consumption in low and middle-income countries (LMICs)
3.6.1.2. Rising prevalence of infectious diseases
3.6.1.3. Development of novel approaches for new antibIoTics for treating bacterial infections and a large number of clinical trials.
3.6.2. Restraints
3.6.2.1. Development of AntibIoTic resistance, driven by misuse of antibIoTics
3.6.2.2. The time taken for the regulatory approval
3.6.3. Opportunities
3.6.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibIoTic-resistant microbial infections.

Chapter 4: ANTIBIoTICS MARKET, BY CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Penicillins
4.2.2.1.1. Market size and forecast
4.2.2.2. Cephalosporins
4.2.2.2.1. Market size and forecast
4.2.2.3. Carbapenems
4.2.2.3.1. Market size and forecast
4.2.2.4. Monobactams
4.2.2.4.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Quinolones
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Macrolides
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

Chapter 5: ANTIBIoTICS MARKET, BY DRUG ORIGIN
5.1. Overview
5.1.1. Market size and forecast
5.2. Natural
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Semisynthetic
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Synthetic
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

Chapter 6: ANTIBIoTICS MARKET, BY SPECTRUM OF ACTIVITY
6.1. Overview
6.1.1. Market size and forecast
6.2. Broad-spectrum antibIoTic
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Narrow-spectrum antibIoTic
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

Chapter 7: ANTIBIoTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. Intravenous
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Others
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country

Chapter 8: ANTIBIoTICS MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. North America antibIoTics market, by country
8.2.2.1. U.S. antibIoTics market by class
8.2.2.2. U.S. antibIoTics market by drug origin
8.2.2.3. U.S. antibIoTics market by spectrum of activity
8.2.2.4. U.S. antibIoTics market by Route of administration
8.2.2.5. Canada antibIoTics market by class
8.2.2.6. Canada antibIoTics market by drug origin
8.2.2.7. Canada antibIoTics market by spectrum of activity
8.2.2.8. Canada antibIoTics market by route of administration
8.2.2.9. Mexico antibIoTics market by class
8.2.2.10. Mexico antibIoTics market by drug origin
8.2.2.11. Mexico antibIoTics market by spectrum of activity
8.2.2.12. Mexico antibIoTics market by route of administration
8.2.3. North America antibIoTics market, by class
8.2.4. North America antibIoTics market, by drug origin
8.2.5. North America antibIoTics market, by spectrum of activity
8.2.6. North America antibIoTics market, by route of administration
8.3. Europe
8.3.1. Key market trends and opportunities
8.3.2. Europe antibIoTics market, by country
8.3.2.1. Germany antibIoTics market by class
8.3.2.2. Germany antibIoTics market by drug origin
8.3.2.3. Germany antibIoTics market by spectrum of activity
8.3.2.4. Germany antibIoTics market by Route of administration
8.3.2.5. France antibIoTics market by class
8.3.2.6. France antibIoTics market by drug origin
8.3.2.7. France antibIoTics market by spectrum of activity
8.3.2.8. France antibIoTics market by route of administration
8.3.2.9. Spain antibIoTics market by class
8.3.2.10. Spain antibIoTics market by drug origin
8.3.2.11. Spain antibIoTics market by spectrum of activity
8.3.2.12. Spain antibIoTics market by route of administration
8.3.2.13. Italy antibIoTics market by class
8.3.2.14. Italy antibIoTics market by drug origin
8.3.2.15. Italy antibIoTics market by spectrum of activity
8.3.2.16. Italy antibIoTics market by route of administration
8.3.2.17. UK antibIoTics market by class
8.3.2.18. UK antibIoTics market by drug origin
8.3.2.19. UK antibIoTics market by spectrum of activity
8.3.2.20. UK antibIoTics market by route of administration
8.3.2.21. Rest of Europe antibIoTics market by class
8.3.2.22. Rest of Europe antibIoTics market by drug origin
8.3.2.23. Rest of Europe antibIoTics market by spectrum of activity
8.3.2.24. Rest of Europe antibIoTics market by route of administration
8.3.3. Europe antibIoTics market, by class
8.3.4. Europe antibIoTics market, by drug origin
8.3.5. Europe antibIoTics market, by spectrum of activity
8.3.6. Europe antibIoTics market, by route of administration
8.4. Asia-Pacific
8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific antibIoTics market, by country
8.4.2.1. Australia antibIoTics market by class
8.4.2.2. Australia antibIoTics market by drug origin
8.4.2.3. Australia antibIoTics market by spectrum of activity
8.4.2.4. Australia antibIoTics market by Route of administration
8.4.2.5. Japan antibIoTics market by class
8.4.2.6. Japan antibIoTics market by drug origin
8.4.2.7. Japan antibIoTics market by spectrum of activity
8.4.2.8. Japan antibIoTics market by route of administration
8.4.2.9. India antibIoTics market by class
8.4.2.10. India antibIoTics market by drug origin
8.4.2.11. India antibIoTics market by spectrum of activity
8.4.2.12. India antibIoTics market by route of administration
8.4.2.13. China antibIoTics market by class
8.4.2.14. China antibIoTics market by drug origin
8.4.2.15. China antibIoTics market by spectrum of activity
8.4.2.16. China antibIoTics market by route of administration
8.4.2.17. Rest of Asia-Pacific antibIoTics market by class
8.4.2.18. Rest of Asia-Pacific antibIoTics market by drug origin
8.4.2.19. Rest of Asia-Pacific antibIoTics market by spectrum of activity
8.4.2.20. Rest of Asia-Pacific antibIoTics market by route of administration
8.4.3. Asia-Pacific antibIoTics market, by class
8.4.4. Asia-Pacific antibIoTics market, by drug origin
8.4.5. Asia-Pacific antibIoTics market, by spectrum of activity
8.4.6. Asia-Pacific antibIoTics market, by route of administration
8.5. LAMEA
8.5.1. Key market trends and opportunities
8.5.2. LAMEA antibIoTics market, by country
8.5.2.1. Brazil antibIoTics market by class
8.5.2.2. Brazil antibIoTics market by drug origin
8.5.2.3. Brazil antibIoTics market by spectrum of activity
8.5.2.4. Brazil antibIoTics market by Route of administration
8.5.2.5. Saudi Arabia antibIoTics market by class
8.5.2.6. Saudi Arabia antibIoTics market by drug origin
8.5.2.7. Saudi Arabia antibIoTics market by spectrum of activity
8.5.2.8. Saudi Arabia antibIoTics market by route of administration
8.5.2.9. South Africa antibIoTics market by class
8.5.2.10. South Africa antibIoTics market by drug origin
8.5.2.11. South Africa antibIoTics market by spectrum of activity
8.5.2.12. South Africa antibIoTics market by route of administration
8.5.2.13. Rest of LAMEA antibIoTics market by class
8.5.2.14. Rest of LAMEA antibIoTics market by drug origin
8.5.2.15. Rest of LAMEA antibIoTics market by spectrum of activity
8.5.2.16. Rest of LAMEA antibIoTics market by route of administration
8.5.3. LAMEA antibIoTics market, by class
8.5.4. LAMEA antibIoTics market, by drug origin
8.5.5. LAMEA antibIoTics market, by spectrum of activity
8.5.6. LAMEA antibIoTics market, by route of administration

Chapter 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. Allergan Plc.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. Merck & Co. Inc.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments
9.6. Mylan N.V.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. Novartis International AG (Sandoz)
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sanofi
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance

List Of Tables
Table 01. Global AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 02. Beta Lactam And Beta Lactamase Inhibitors AntibIoTics Market, By Type, 2017-2025 ($Million)
Table 03. AntibIoTics Market For Beta Lactam And Beta Lactamase Inhibitors, By Region, 2017-2025 ($Million)
Table 04. AntibIoTics Market For Quinolones, By Region, 2017-2025 ($Million)
Table 05. Antibitotics Market For Macrolides, By Region, 2017-2025 ($Million)
Table 06. AntibIoTics Market For Others, By Region, 2017-2025 ($Million)
Table 07. Global AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 08. AntibIoTics Market For Natural, By Region, 2017-2025 ($Million)
Table 09. AntibIoTics Market For Semisynthetic, By Region, 2017-2025 ($Million)
Table 10. AntibIoTics Market For Synthetic, By Region, 2017-2025 ($Million)
Table 11. Global AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 12. AntibIoTics Market For Broad-Spectrum AntibIoTic, By Region, 2017-2025 ($Million)
Table 13. AntibIoTics Market For Narrow-Spectrum AntibIoTic, By Region, 2017-2025 ($Million)
Table 14. Global AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 15. AntibIoTics Market For Oral, By Region, 2017-2025 ($Million)
Table 16. AntibIoTics Market For Intravenous, By Region, 2017-2025 ($Million)
Table 17. AntibIoTics Market For Others, By Region, 2017-2025 ($Million)
Table 18. Global AntibIoTics Market Revenue, By Region, 2017-2025 ($Million)
Table 19. North America AntibIoTics Market, By Country, 2017-2025 ($Million)
Table 20. U.S. AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 21. U.S. AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 22. U.S. AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 23. U.S. AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 24. Canada AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 25. Canada AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 26. Canada AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 27. Canada AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 28. Mexico AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 29. Mexico AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 30. Mexico AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 31. Mexico AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 32. North America AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 33. North America AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 34. North America AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 35. North America AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 36. Europe AntibIoTics Market, By Country, 2017-2025 ($Million)
Table 37. Germany AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 38. Germany AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 39. Germany AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 40. Germany AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 41. France AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 42. France AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 43. France AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 44. France AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 45. Spain AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 46. Spain AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 47. Spain AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 48. Spain AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 49. Italy AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 50. Italy AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 51. Italy AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 52. Italy AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 53. UK AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 54. UK AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 55. UK AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 56. UK AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 57. Rest Of Europe AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 58. Rest Of Europe AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 59. Rest Of Europe AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 60. Rest Of Europe AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 61. Europe AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 62. Europe AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 63. Europe AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 64. Europe AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 65. Asia-Pacific AntibIoTics Market, By Country, 2017-2025 ($Million)
Table 66. Australia AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 67. Australia AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 68. Australia AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 69. Australia AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 70. Japan AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 71. Japan AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 72. Japan AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 73. Japan AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 74. India AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 75. India AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 76. India AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 77. India AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 78. China AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 79. China AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 80. China AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 81. China AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 82. Rest Of Asia-Pacific AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 83. Rest Of Asia-Pacific AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 84. Rest Of Asia-Pacific AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 85. Rest Of Asia-Pacific AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 86. Asia-Pacific AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 87. Asia-Pacific AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 88. Asia-Pacific AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 89. Asia-Pacific AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 90. LAMEA AntibIoTics Market, By Country, 2017-2025 ($Million)
Table 91. Brazil AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 92. Brazil AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 93. Brazil AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 94. Brazil AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 95. Saudi Arabia AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 96. Saudi Arabia AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 97. Saudi Arabia AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 98. Saudi Arabia AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 99. South Africa AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 100. South Africa AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 101. South Africa AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 102. South Africa AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 103. Rest Of LAMEA AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 104. Rest Of LAMEA AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 105. Rest Of LAMEA AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 106. Rest Of LAMEA AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 107. LAMEA AntibIoTics Market, By Class, 2017-2025 ($Million)
Table 108. LAMEA AntibIoTics Market, By Drug Origin, 2017-2025 ($Million)
Table 109. LAMEA AntibIoTics Market, By Spectrum Of Activity, 2017-2025 ($Million)
Table 110. LAMEA AntibIoTics Market, By Route Of Administration, 2017-2025 ($Million)
Table 111. Abbott: Company Snapshot
Table 112. Abbott: Operating Segments
Table 113. Abbott: Product Portfolio
Table 114. Allergan: Company Snapshot
Table 115. Allergan: Operating Segments
Table 116. Allergan: Product Portfolio
Table 117. Roche: Company Snapshot
Table 118. Roche: Operating Segments
Table 119. Roche: Product Portfolio
Table 120. Gsk: Company Snapshot
Table 121. Gsk: Operating Segments
Table 122. Gsk: Product Portfolio
Table 123. Merck: Company Snapshot
Table 124. Merck: Operating Segments
Table 125. Merck: Product Portfolio
Table 126. Mylan: Company Snapshot
Table 127. Mylan: Operating Segments
Table 128. Allergan: Product Portfolio
Table 129. Novartis Ag: Company Snapshot
Table 130. Novartis: Operating Segments
Table 131. Novartis Ag: Product Portfolio
Table 132. Pfizer: Company Snapshot
Table 133. Pfizer: Operating Segments
Table 134. Pfizer: Product Portfolio
Table 135. Sanofi: Company Snapshot
Table 136. Sanofi: Operating Segments
Table 137. Sanofi: Product Portfolio
Table 138. Teva: Company Snapshot
Table 139. Teva: Operating Segments
Table 140. Teva: Product Portfolio

List of Figures
Figure 01. AntibIoTics Market Segmentation
Figure 02. Top Investment Pockets In The Global AntibIoTics Market
Figure 03. Top Winning Strategies, By Year, 2015-2018*
Figure 04. Top Winning Strategies, By Development, 2015-2018* (%)
Figure 05. Top Winning Strategies, By Company, 2015-2018*
Figure 06. Market Share Analysis, 2017
Figure 07. Moderate Bargaining Power Of Buyers
Figure 08. High Bargaining Power Of Suppliers
Figure 09. High Threat Of New Entrants
Figure 10. Moderate Threat Of Substitution
Figure 11. Moderate Competitive Rivalry
Figure 12. Penicillins AntibIoTics Market, 2017-2025 ($Million)
Figure 13. Cephalosporins AntibIoTics Market, 2017-2025 ($Million)
Figure 14. Carbapenems AntibIoTics Market, 2017-2025 ($Million)
Figure 15. Monobactams AntibIoTics Market, 2017-2025 ($Million)
Figure 16. Comparative Analysis Of AntibIoTics Market For Beta Lactam And Beta Lactamase Inhibitors, By Country, 2017 & 2025 ($Million)
Figure 17. Comparative Analysis Of AnitbIoTics Market For Quinolones, By Country, 2017 & 2025 ($Million)
Figure 18. Comparative Analysis Of AntibIoTics Market For Macrolides, By Country, 2017 & 2025 ($Million)
Figure 19. Comparative Analysis Of AnitbIoTics Market For Others, By Country, 2017 & 2025 ($Million)
Figure 20. Comparative Analysis Of AntibIoTics Market For Natural, By Country, 2017 & 2025 ($Million)
Figure 21. Comparative Analysis Of AntibIoTics Market For Semisynthetic, By Country, 2017 & 2025 ($Million)
Figure 22. Comparative Analysis Of AntibIoTics Market For Synthetic, By Country, 2017 & 2025 ($Million)
Figure 23. Comparative Analysis Of AntibIoTics Market For Broad-Spectrum AntibIoTic, By Country, 2017 & 2025 ($Million)
Figure 24. Comparative Analysis Of AntibIoTics Market For Narrow-Spectrum AntibIoTic, By Country, 2017 & 2025 ($Million)
Figure 25. Comparative Analysis Of AntibIoTics Market For Oral, By Country, 2017 & 2025 ($Million)
Figure 26. Comparative Analysis Of AntibIoTics Market For Intravenous, By Country, 2017 & 2025 ($Million)
Figure 27. Comparative Analysis Of AntibIoTics Market For Others, By Country, 2017 & 2025 ($Million)
Figure 28. Abbott: Net Sales, 2015-2017 ($Million)
Figure 29. Abbott: Revenue Share By Segment, 2017 (%)
Figure 30. Abbott: Revenue Share By Geography, 2017 (%)
Figure 31. Allergan: Net Sales, 2015-2017 ($Million)
Figure 32. Allergan: Revenue Share By Segment, 2017 (%)
Figure 33. Roche: Net Sales, 2015-2017 ($Million)
Figure 34. Roche: Revenue Share By Segment, 2017 (%)
Figure 35. Gsk: Net Sales, 2015-2017 ($Million)
Figure 36. Gsk: Revenue Share By Segment, 2017 (%)
Figure 37. Gsk: Revenue Share By Geography, 2017 (%)
Figure 38. Merck: Net Sales, 2015-2017 ($Million)
Figure 39. Merck: Revenue Share By Segment, 2017 (%)
Figure 40. Merck: Revenue Share By Geography, 2017 (%)
Figure 41. Mylan: Net Sales, 2015-2017 ($Million)
Figure 42. Mylan: Revenue Share By Geography, 2017 (%)
Figure 43. Novartis: Net Sales, 2015-2017 ($Million)
Figure 44. Novartis: Revenue Share By Segment, 2017 (%)
Figure 45. Novartis: Revenue Share By Geography, 2017 (%)
Figure 46. Pfizer: Net Sales, 2015-2017 ($Million)
Figure 47. Pfizer: Revenue Share By Segment, 2017 (%)
Figure 48. Pfizer: Revenue Share By Geography, 2017 (%)
Figure 49. Sanofi: Net Sales, 2015-2017 ($Million)
Figure 50. Sanofi: Revenue Share By Segment, 2017 (%)
Figure 51. Sanofi: Revenue Share By Geography, 2017 (%)
Figure 52. Teva: Net Sales, 2015-2017 ($Million)
Figure 53. Teva: Revenue Share By Segment, 2017 (%)
Figure 54. Teva: Revenue Share By Geography, 2017 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled, 'Antibiotics Market by Class, Drug Origin, Spectrum of Activity, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2025,' the global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025. The beta lactam & beta lactamase inhibitors segment accounted for more than three-fifth of the total market share in 2017.

Antibiotic is a medication used to either inhibit or prevent bacterial infections referred as bactericidal and bacteriostatic antibiotics, respectively. Various types of antibiotics such as penicillin, cephalosporin, carbapenem, and monobactam are available in pharmacies and hospitals that are used to treat infectious diseases.

The antibiotics market is expected to exhibit significant growth during the forecast period, due to rise in demand for new generation antibiotics that can resolve the issue of antimicrobial resistance. In addition, development of novel approaches for new antibiotics for treating bacterial infections and increase in number of clinical trials supplement the growth of the antibiotics market. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for the regulatory approval restrain the market growth. On the contrary, the discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to provide new opportunities for market players in the near future.

Based on class, the global antibiotics market is categorized into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. The quinolones segment is anticipated to exhibit the highest CAGR during forecast period, due to upsurge in demand for broad-spectrum, bactericidal activity; new generation quinolones; enhanced oral bioavailability; superior tissue penetration; and improved safety & tolerability.

By route of administration, the market is classified into oral, intravenous, and others. The intravenous segment was the major revenue contributor in 2017, and is projected to continue this trend during the forecast period, due to increase in incidence of severe infections. Moreover, as intravenous antibiotics are administered in higher concentrations, they reach in the tissues faster as compared to oral antibiotics.

Asia-Pacific is expected to remain dominant throughout the forecast period attributable to increased antibiotics consumption, their easy availability, and rise in sale of over-the-counter drugs. However, LAMEA is expected to experience the highest growth rate during the forecast period, majorly due to no obligations on antibiotics use in this region.

The report provides a comprehensive analysis of the key players operating in the global antibiotics market, namely, Abbott Laboratories, Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

The other players in the value chain include Aurobindo Pharma, Bayer HealthCare, Eli Lilly, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, and others.

Key Findings of the Antibiotics Market:

Based on spectrum of activity, the broad-spectrum antibiotic segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 2.4% from 2018 to 2025.
Depending on route of administration, the oral segment is expected to exhibit the highest CAGR during the forecast period.
By drug origin, the semisynthetic segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period.
U.S. generated the highest revenue in the global antibiotics market in 2017, accounting for more than one-fifth of the global market in 2017.
LAMEA is estimated to grow at a CAGR of 3.5% during the forecast period.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4744610
Adroll
adroll